|UNITED
STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549



FORM 10-K
|-----------------------------------------------------------------------------------

|[X] |  | ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE  SECURITIES EXCHANGE ACT OF 1934
|--- |  | -------------------------------------------------------------------------------------

| | For
the Fiscal Year Ended June 30, 2001
| | ---------------------------------------

|OR
|--

|[  ] |  | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  SECURITIES EXCHANGE ACT OF 1934
|---- |  | -----------------------------------------------------------------------------------------

| | Commission File Number 0-11250
| | ------------------------------

|DIONEX CORPORATION(Exact name of registrant as specified in its charter)
|------------------------------------------------------------------------

|Delaware                                                      |  | 94-2647429                                                                                                                   | 
|------------------------------------------------------------- |  | ---------------------------------------------------------------------------------------------------------------------------- | 
|(State or other jurisdiction ofincorporation or organization) |  | (I.R.S. Employer
                                                                                        Identification No.) | 

|1228 Titan Way, Sunnyvale, California    |  | 94085      | 
|---------------------------------------- |  | ---------- | 
|(Address of principal executive offices) |  | (Zip Code) | 

|Registrants telephone number,
including area code (408) 737-0700


Securities registered pursuant to
Section 12(b) of the Act: None


Securities registered pursuant to
Section 12(g) of the Act:



Common Stock, par value
$.001 per share



Indicate by check mark whether the
registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.    YES  [X]   NO  [   ]



Indicate by check mark if disclosure
of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and
will not be contained, to the best of registrants knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [X]


The aggregate market value
of the Registrants Common Stock held by nonaffiliates on September 18,
2001 based upon the closing price of such stock as of such date) was
$555,030,000.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|As of September 18, 2001,
22,120,489 shares of the Registrants Common Stock were outstanding.


Portions of the
Registrants 2001 Annual Report to Stockholders are incorporated by
reference in Parts I, II and IV of this Report. Portions of the
Registrants definitive Proxy Statement for the Annual Meeting of
Stockholders to be held on October 26, 2001 are incorporated by reference in
Part III of this Report.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|TABLE OF CONTENTS



PART I
|---------------------------

|Item 1. |  | Business                                            |  | 1  | 
|------- |  | --------------------------------------------------- |  | -- | 
|Item 2. |  | Properties                                          |  | 15 | 
|Item 3. |  | Legal Proceedings                                   |  | 15 | 
|Item 4. |  | Submission of Matters to a Vote of Security Holders |  | 15 | 

|PART II
|-------

|Item 5.  |  | Market for the Registrants Common Equity andRelated Stockholder Matters              |  | 18 | 
|-------- |  | ------------------------------------------------------------------------------------- |  | -- | 
|Item 6.  |  | Selected Consolidated Financial Data                                                  |  | 18 | 
|Item 7.  |  | Managements Discussion and Analysis ofFinancial Condition and Results of Operations. |  | 18 | 
|Item 7A. |  | Quantitative and Qualitative Disclosures AboutMarket Risk                             |  | 18 | 
|Item 8.  |  | Financial Statements and Supplementary Data                                           |  | 18 | 
|Item 9.  |  | Changes in and Disagreements with AccountantsOn Accounting and Financial Disclosure   |  | 18 | 

|PART III
|--------

|Item 10. |  | Directors and Executive Officers of the Registrant            |  | 19 | 
|-------- |  | ------------------------------------------------------------- |  | -- | 
|Item 11. |  | Executive Compensation                                        |  | 19 | 
|Item 12. |  | Security Ownership of Certain BeneficialOwners and Management |  | 19 | 
|Item 13. |  | Certain Relationships and Related Transactions                |  | 19 | 

|PART IV
|-------

|Item 14. |  | Exhibits, Financial Statement Schedules, andReports on Form 8-K |  | 20 | 
|-------- |  | --------------------------------------------------------------- |  | -- | 

|Exhibit Index |  | 21 | 
|------------- |  | -- | 

|
|

|PART I
|------

|Item 1. |  | BUSINESS
|------- |  | --------

|Dionex
Corporation* designs, manufactures, markets and services analytical instrumentation and
related accessories and chemicals. The Companys products are used to analyze chemical
substances in the environment and in a broad range of industrial and scientific
applications. Since July 1, 1999, there have been no material changes in the mode of
conducting the business of the Company.



Industry
Segment Information


The
Company operates in a single industry segment consisting of analytical instruments and
related services.


Products


Dionex
develops, manufactures, markets and services a range of liquid chromatography systems,
sample preparation devices and related products that are used by chemists to separate and
quantify the individual components of complex chemical mixtures in many major industrial,
research and laboratory markets. Typically, the Companys chromatography systems consist
of several components including a specially designed liquid pumping and flow system, a
sample injection system, a separator column, a suppressor or other post-column device, a
detector and a data collection and analysis system. These components are designed to be
modular so that systems can be configured to meet the particular analytical requirements
of individual customers. Moreover, individual components may be sold separately to
existing customers that wish to expand their systems.


The
Companys liquid chromatography systems are currently focused in several product areas:
ion chromatography (IC), high performance liquid chromatography (HPLC) and capillary and
nano-scale HPLC. The Company also provides sample extraction systems. In addition to
these product areas, the Company develops and manufactures columns, detectors, data
analysis systems and other products. Each of these product areas is described below.


Ion
Chromatography  Ion Chromatography is a form of
chromatography that separates ionic (charged) molecules, usually found in
water-based solutions, and typically separates and detects them based on their
electrical conductivity. The sale of Dionex IC systems and related columns,
suppressors, detectors, automation and other products accounts for approximately
two-thirds of the Companys revenues.
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | *Unless  the
context otherwise requires, the terms Dionex and the Company as used herein include
Dionex Corporation, a Delaware corporation, and its subsidiaries. Dionex was initially
incorporated in California in 1980. In 1986, the Company reincorporated in Delaware.
| |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|1
|-

|Dionex
IC products are used in a wide range of applications, including environmental monitoring,
quality control of pharmaceuticals, corrosion monitoring, evaluation of raw materials,
quality control of industrial processes products, research and development, and
regulation of the chemical composition of food, beverage and cosmetic products. Major
customers include environmental testing laboratories, life science and food companies,
chemical and petrochemical firms, power generating facilities, electronics manufacturers,
government agencies and academic institutions.


The Company offers the
following products for IC:


DX-80
Ion Analyzer


In
fiscal 2001, the Company introduced the DX-80, a routine simple to use ion analyzer. The
DX-80 was designed for customers with little or no knowledge of ion chromatography. The
DX-80 has preset calibration and methods and is ideal for analysis of cation anions and
cations. The DX-80 is marketed worldwide.


DX-120
IC System


In
fiscal 1996, the Company introduced the DX-120, a cost-effective IC system for customers
that need simple, dedicated instrumentation for routine ion analysis. The DX-120 was
designed for improved reliability and automation, allowing for quick set-up, simple
operation and high quality isocratic performance. The DX-120 is marketed worldwide.



DX-320
IC System


In
fiscal 2000, the Company introduced the DX-320, a high-performance, dedicated IC system
with more versatility than the DX-120. The DX-320 runs isocratic and gradient
applications and can be used with the EG 40 Eluent Generator. The heart of the DX-320 is
the IC25 Integrated Pump and Detector, a compact unit enabling conductivity detection and
a dual piston pumping system.

2
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|DX-600 IC System and PeakNet 6


In
fiscal 2000, the Company introduced the DX-600 IC system, to provide the most powerful
and flexible ion chromatography. The system is modular, offering the GP50-II gradient
pump and IP25 isocratic pump, the LC20 enclosure or the LC25 or LC30 chromatography
ovens, advanced autosampler options, and the ED50 electrochemical, CD25 conductivity,
AD25 absorbance and PDA-100 photodiode array methods of detection. The advanced
electronics and modularity of the system provide enough versatility to cover any variety
of demanding IC applications. The DX-600 is automated and its data is collected and
managed by PeakNet 6 chromatography software, also introduced by the Company in fiscal
2000. PeakNets data query, signatures/signoffs and system wellness provisions allow
greater power and simplicity in running IC. PeakNet 6 replaced the Companys PeakNet 5
series software, just as the DX-600 replaced the DX-500 IC system. The DX-600 IC system
and PeakNet 6 software are marketed worldwide.


Process Instrumentation


In
fiscal 1998, the Company began shipping the DX-800, the next generation continuous
on-line monitoring system. The DX-800 uses industry standard PC-based automation, similar
to that used in laboratory chromatography. Major applications for the Companys DX-800
are in the power industry for the continuous monitoring of corrosive contaminants in
boiler water, the semiconductor industry for continuous monitoring of contaminants in
high purity water and continuous monitoring of biological and chemical synthesis
processes. The DX-800 is marketed worldwide.


High Performance
Liquid Chromatography  HPLC is a form of chromatography
that separates molecules such as proteins, carbohydrates, amino acids,
pharmaceuticals and chemicals and identifies them by measuring the amount of
light that the molecules absorb or emit when exposed to a light source. The
Companys customers include biological research and biotechnology groups,
pharmaceutical and other industrial companies.


The Company offers the
following products for HPLC:


Summit HPLC System and CHROMELEON 6
Software


In
fiscal 2000, the Company introduced a new version of its Summit HPLC System, including a
new photodiode array detector, the PDA-100 and updated CHROMELEON 6 chromatography
software. The Summit HPLC system includes the P580A low pressure gradient pump or P580A
high pressure gradient pump, the ASI-100 Autosampler with optional thermal cooling and
operates using CHROMELEON 6 software. This powerful software package now offers PDA
control, multi-instrument control (including control of other companies equipment),
validation provisions and many other powerful features. The Summit HPLC system and
CHROMELEON 6 chromatography software are marketed worldwide.



3
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|BioLC®System


In
fiscal 2000, the Company introduced the BioLC system. The BioLC replaces the fiscal 1999
version of the Companys AAA-Direct system. The BioLC features an inert, metal-free,
polyetheretherketone flow path to preserve chemically unstable biomolecules. The BioLC
provides third-generation pumps and detectors, including the GS50 gradient pump, the
premier pump for BioLC, and a choice of the ED50 electrochemical detector, AD25
absorbance detector and PDA-100 photodiode array detector. These options allow for a wide
range of applications so that analysts can quantify carbohydrates, amino acids, proteins
and peptides, nucleic acids and small biomolecules using the BioLC. The instrument ships
with PeakNet 6 chromatography software.


AQA Mass Spectrometer


In
fiscal 2000, the Company signed an agreement with Thermo Electron to sell their Finnigan
AQA massspectrometer(MS) Dionex Summit HPLC, BioLC and DX-600 IC systems. The
relationship with Thermo Electron allows Dionex to market LC/MS and IC/MS systems to
existing and new customers worldwide, particularly in the pharmaceutical market, but also
for environmental testing, drug, beverage and food testing and many other applications.
AQA is a compact, benchtop, single quadrupole mass detector for HPLC/MS and IC/MS. The
standard system is supplied with both Electrospray (ESI) and Atmospheric Pressure
Chemical Ionization (APCI) for maximum analytical flexibility and the patented AQAwash
for system robustness. The relationship with Thermo Electron enables Dionex to reach
chemists desiring MS capabilities who previously were not among the Companys potential
customers.


Capillary-/nano scale
HPLC  Capillary and nano scale liquid chromatography is a
form of HPLC that uses flow rate and size of samples are much smaller than
traditional HPLC.


The Company offers the
following products for capillary and nano scale HPLC.


UltiMate Capillary-and Nano
HPLC System


In
fiscal 2001, the Company introduced the UltiMate system, a dedicated miscroseparation
system. UltiMate consists of a high-precision pump that is coupled with a proprietary
method of flow splitting to provide accurate reproducible isocratic and gradient
separations from 40 ul/min. to 100 nL/min. The UltiMate also has a specially developed UV
detector. This detector coupled with our proprietary capillary flow cells allows the most
sensitive UV detection in microcolumn separations. Accessories for the Ultimate system
include the FAMOS autosampler and the Switchos module for use with large volume samples.




4
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Sample Extraction  The Company offers Accelerated Solvent Extraction® (ASE®)
for automated sample extraction. In fiscal 2000, the Company introduced the
ASE 300, an automated sample extraction instrument for large samples up to 100
mL. In all respects, except sample capacity handling, the ASE 300 is similar to
the ASE 200, introduced by the Company in fiscal 1995. Both ASE systems extract
solid samples using common solvents at elevated temperatures and pressures. The
ASE systems extract solid samples in an automated fashion using the same
solvents used in traditional soxhlet techniques. Competitive techniques include
soxhlet, sonication, microwave extraction and supercritical fluid extraction.
The ASE 200 and 300 systems offer several advantages over other solvent based
extraction techniques including lower solvent consumption, reduced
extraction time, higher throughput through automation and ease of use. ASE 200
and 300 systems are used worldwide for a number of environmental, industrial and
food and beverage applications. In fiscal 1997, the Company enhanced its ASE 200
system by introducing the ASE 200 Solvent Controller Module, which automates the
delivery of multiple solvents to the ASE 200 system, and AutoASE, an
add-on software feature which allows control of up to eight ASE 200 systems from
one location, as well as methods storage and documentation. Both the Solvent
Controller Module and AutoASE are also used with the ASE 300 system. In fiscal
2000, the Company introduced several new applications for the ASE 200 and ASE
300. These applications include time and labor savings for the extraction of
polymers and environmental samples.


Automation
Products  As part of its efforts to make chemical analyses
simpler, faster and more reliable, Dionex offers a family of products that
automate sample handling, system operation and data analysis for chromatography
systems. These products include PeakNet, PeakNet PA for Process Analysis and
CHROMELEON. In addition, several automated sample injection modules are
available for IC and HPLC applications.


Software


PeakNet
6, introduced in fiscal 2000, is the Companys latest release of Windows-based
applications for IC and BioLC. PeakNet 6 makes possible the use of multi-featured, high
performance computer systems to automate control, data acquisition, analysis and
reporting for the DX-120, DX-320, DX-600, DX-800 and BioLC systems. In fiscal 1994, the
PeakNet PC-based Chromatography Workstation was first introduced. In fiscal 1997, the
Company introduced its latest version of the software, PeakNet 5.0, a 32-bit automation
product designed for use with Windows 95 and Windows NT. In fiscal 1998, the Company
enhanced its PeakNet chromatography software by introducing PeakNet 5.1. This release
added new capabilities to the PeakNet software, including full control and support of the
EG40 and enhanced reporting capabilities. PeakNet 6 continues to build on the previous
software while adding many technological advances made possible by the Companys
acquisition of Softron GmbH in October 1998. These advances include multi-vendor support,
provisions for electronic signature and sign-off, SQL-based data management/retrieval,
security features, system wellness, and validation measures.



5
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|The
Company introduced in fiscal 2000, as part of the Summit HPLC system, the CHROMELEON 6
data management system. Like PeakNet 6, CHROMELEON 6 is a 32-bit application designed to
run on Windows 95, 98 and Windows NT and even mixed platforms. CHROMELEON operates most
liquid and gas chromatography systems from a single user interface. It is an easy to use,
flexible data system with a built-in SQL database and client/server architecture.


In
fiscal 1994, the universal interface (UI20) module was added to PeakNet. It allows
PeakNet workstations to accept data from other Dionex instruments, as well as instruments
manufactured by other vendors. A revision of the PeakNet software was also introduced at
that time to support the new interfacing capabilities.


In
fiscal 1999, the universal chromatography interface (UCI-100) module was added to
Chromeleon. It allows Chromeleon workstations to accept data from a wide variety of
instruments produced by third party vendors.


Autosamplers


In
fiscal 1994, the Company introduced the AS40 Automated Sample Injection module (AS40).
The AS40 is a low-cost, metal-free, rugged automated sample loading device designed
especially for ion chromatography applications. The AS40 can be used with the DX-120 and
DX-600 series.


In
September 1998, the Company introduced the AS50 Auto-Select Autosampler for use with the
DX-500 ion chromatography system. The AS50 Autosampler is a high-performance, random vial
access autosampler with automated sample preparation which is now used in BioLC, DX-320
and DX-600 systems.


In
fiscal 2000 the Company introduced the ASI-100 Autosampler with optional thermal control
for temperature-sensitive samples. The ASI-100 provides speed, simplicity, reliability
and precision with an innovative in-line split-loop injection technology. The removable
carousels and programmable needle depth allows the ASI-100 to accommodate a variety of
sample vials and sizes. The ASI-100 replaces the Gina 50 autosampler, introduced with the
Summit predecessor in fiscal 1999.


In
fiscal 2001, the Company introduced the FAMOS Micro Autosampler. The FAMOS is a fully
automated micro autosampler for sample injections from a 96 or 385 well plates, PCR
tubes, or conventional 1.5 ml vials. The unique design allows for automated injection of
volumes ranging from 50 nanoliters to up 5 microliters. FAMOS has a proprietary injection
technique that guarantees high performance and virtually no sample dispersion. The FAMOS
is marketed with the UltiMate System.
6
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Columns and SuppressorsA
chromatography column generally consists of a hollow cylinder packed under high pressure
with a chemical resin. The columns function is to separate various chemical
components in a sample. The Company develops and manufactures its own resins using
proprietary processes. Dionex currently manufactures and markets a broad range of column
types designed for particular applications in the liquid chromatography market.


We
introduced several new columns during fiscal 2001. The IonPac® AS15 anion exchange
column provides excellent retention and resolution in the fast separation of trace level
concentrations of inorganic anions and low molecular weight organic acids. The IonPac
CS16 high-capacity cation exchange column is designed for the determination of disparate
concentration ratios of sodium and ammonium in approximately 20 minutes using a simple
aqueous eleunt. The CS16 column separates lithium, sodium, ammonium, potassium, magnesium
and calcium in drinking water, waste water, ground water and other diverse sample
matrices.


These
products follow a steady stream of columns and chemistries introduced in the previous two
years, including the IonPac AS14A, IonPac CS12A, IonPacAS17, IonPac AS16, ProPac WCX-10,
ProPac SCX-10, ProPac SAX-10 and ProPac WAX-10.


In
addition to columns, Dionex manufactures suppressors that are used to enhance detection
in ion chromatography. The Company has proprietary positions in the technology of
suppression used in ion chromatography as well as in the application of suppression
techniques. The Companys suppressors lower background conductivity while allowing
separations using higher capacity columns and more concentrated eluents (liquids used to
carry a sample through a liquid chromatography system). In fiscal 1993, Dionex enhanced
its suppression technology with the introduction of a new AutoSuppression® product. The
product, called the Self-Regenerating Suppressor (SRS®), enhances IC performance while
operating with low maintenance requirements. In fiscal 1997, the Company introduced the
SRS-II, designed to allow use with a wide range of solvents at various temperatures.


In
fiscal 1998, the Company introduced the SRS-Ultra, the next generation in the SRS line of
suppressors. The SRS-Ultra provides superior performance for trace level ion
chromatography and is used in the DX-600 and DX-320 IC systems, and DX-120 IC systems.



7
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|In
fiscal 2001, the Company introduced the Atlas Electrolytic Suppressor. The Atlas
suppressor provides improved sensitivity, lower noise and faster start-up over our
previous, industry leading AutoSuppression® technology, raising the bar even higher in
the technology of electrolytic suppression for IC. The Atlas suppressor utilizes an
innovative ion exchange monolith and flow distribution disks, producing maximum capacity
with minimal dead volume. The Atlas suppressor is ideal for most IC applications
requiring carbonate eluents. The Atlas works with our DX-600 and DX-320 systems, and can
be extended to the DX-120 and DX-500 IC systems through the use of an external power
supply.


In
fiscal 2001, we introduced the new MMS III MicroMembrane Suppressor for ion
chromatography with the new displacement chemical regeneration mode of operation. The MMS
III can be used with all Dionex ion exchange columns and is recommended for the anion and
cation separations using eluents containing solvents. The displacement chemical
regeneration mode overcomes the need for regenerant flow control and provides a simple
means to deliver regenerant and allows unattended and effortless operation, offering an
option to AutoRegen® or Pressurized bottle modes.


Immediately
after the end of fiscal 2001, we introduced our Acclaim line of silica-based
reversed-phase columns for small molecule applications, which we were developing
throughout fiscal 2001. These columns are manufactured by Dionex and were developed to
expand our product offerings in the HPLC market. The columns come in two particle sizes
and two different chemistries, with 28 configurations. Dionex plans to introduce
additional silica-based columns in fiscal 2002.


8
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|DetectorsDetectors are
used to measure the quantity of various sample components after they have been separated
in a chromatography column. Dionex currently offers several detector products based on
conductivity, electrochemistry, fluorescence and absorbance, including the new PDA-100
photodiode array detector, AD25 absorbance detector and several other new detectors
introduced in fiscal 2000. This range of detectors is designed to meet customer
requirements for analysis of organics, inorganics, metals, amino acids, biological
compounds and pharmaceuticals. The Company introduced as part of the Summit HPLC system
the PDA-100 and the UVD 170S and UVD 340S detectors. The UVD 170S simultaneously monitors
four wavelengths providing the highest sensitivity available in a multi-channel UV-VIS
detector.


Service and OtherThe
Company also generates revenue from its Customer Service organization through service
contracts, spare part sales, customer training and sales of other related products and
services. (See Technical Support, Installation and Service below.)


Marketing
and Customers


The
Companys market strategy is twofold. First, in those applications where Dionex
technology is well established, the Company works to increase demand for its
chromatography systems through direct mailings, advertising in trade publications,
seminars and workshops, conferences and expositions, and direct sales calls. Growth in
these markets results from identifying new customers in existing sales regions, extending
geographic penetration and increasing demand for the Companys products and technical
support capabilities among existing customers.


The
second component of the Companys marketing strategy is to work closely with existing and
potential customers to develop new applications. Technical support staff assist such
customers in problem definition, development of new applications needed to solve problems
and providing user training and ongoing user support. By combining this support function
with direct sales efforts, the Company works to increase the range of applications and
the potential market for its products.


The
Company currently markets and distributes its products and services through its own sales
force in the United Kingdom, Germany, Italy, France, the Netherlands, Belgium,
Switzerland, Austria, Denmark, Japan, China, Canada and the United States. In each of
these countries, the Company maintains one or more local sales offices in order to
service customers in regional markets. In other international locations where it does not
have a direct sales force, the Company has developed a network of distributors and sales
agents.



9
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|The
Companys products are used extensively in environmental analysis and by the
pharmaceutical, life science, biotechnology, chemical, petrochemical, power generation,
food and beverage and electronics industries. Its customers include a number of the
largest industrial companies worldwide, as well as government agencies, research
institutions and universities. Geographically, sales to customers outside of North
America accounted for 60% of consolidated sales in fiscal 2001, 58% of consolidated sales
in fiscal 2000 and 62% of consolidated sales in fiscal 1999. No single customer accounted
for 10% or more of the Companys sales in fiscal 2001, 2000 or 1999.


Demand
for the Companys products is dependent upon the size of the markets for its
chromatography systems, the level of capital expenditures of the Companys customers, the
rate of economic growth in the Companys major markets and competitive considerations.
There can be no assurances that the Companys results of operations will not be adversely
impacted by a change in any of the factors listed above. The Company believes that demand
for its products does not exhibit any significant seasonal pattern.


Dionex
manufactures its products based upon its forecast of customer demand and maintains
inventories of completed modules in advance of receipt of firm orders from its customers.
Orders are generally placed by the customer on an as-needed basis, and products are
usually shipped within four to six weeks after receipt of an order. Dionex does not
maintain a substantial backlog, and backlog as of any particular date may not be
indicative of the Companys actual sales in any succeeding period. The level of backlog
at June 30, 2001 was $21.6 million and at June 30, 2000 was $23.1 million.


Competition


Competition
in the Companys business segment is based upon the performance capabilities of the
analytical instrument, technical support and after-market service, the manufacturers
reputation as a technological leader and the selling price. Management believes that
performance capabilities are the most important of these criteria. Customers measure
system performance in terms of sensitivity (the ability to discern minute quantities of a
particular sample component), selectivity (the ability to distinguish between similar
components), speed of analysis and the breadth of samples that the system can effectively
analyze. Management believes that Dionex enjoys a favorable reputation in terms of
performance capabilities, technical support and service.


Companies
competing with Dionex in the analytical instruments market include Agilent Technologies,
Inc., PerkinElmer Inc., Varian Inc., Shimadzu Corporation, Thermo Electron Corporation
and Waters Corporation. The Company believes no single competitor has a dominant position
in the analytical instruments market.



10
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|The
Company believes it has a major position in IC, one of many different analytical
techniques. Dionex IC systems generally compete with a number of analytical techniques
used in identifying and quantifying ionic and polar compounds. The two primary sources of
competition for ion chromatography are conventional manual and automated wet chemistry
procedures and certain modified liquid chromatography systems. Some suppliers of liquid
chromatography systems have developed a single column ion chromatography (SCIC) method
that does not use a suppressor device. SCIC methods compete favorably with Dionex ion
chromatography for the analysis of a limited number of ions and in situations when
chemical composition of the sample is not complex or when high sensitivity is not
required. The introduction in 1993 by the Company of AutoSuppression technology
considerably improves the ease of use of chemical suppression. In addition to SCIC
products, the Companys competitors also offer other products to compete in ion
analysis and chromatography products using technology similar to that offered by the
Company in earlier generation modules during the 1980s. Companies competing with
Dionex in IC included such vendors as Alltech Associates, Lachat, Metrohm Ltd, Shimadzu
Corporation, Waters Corporation and other smaller companies.


The
Company believes it has a small but growing share in HPLC, one of many different
analytical techniques.


The
Companys Summit HPLC system competes directly with other manufacturers HPLC systems in
traditional HPLC applications. Dionex believes that the Summit HPLC system has certain
benefits over competing systems, including advanced pump technology and a high
performance autosampler. Coupled with the CHROMELEON software package, this system
provides customers a state-of-the-art HPLC system for their analytical needs.


The
Companys DX-600 Series also competes directly with other manufacturers HPLC systems in
certain traditional HPLC applications. Dionex is a relatively new entrant in the highly
competitive HPLC and biological separations markets. Nonetheless, management believes
that the DX-600 Series and BioLC systems has certain benefits over competing systems,
including a non-metallic flow path and the capability of performing gradient ion
chromatography, as well as HPLC, on a single analytical system. Competitors of the
Company in HPLC include such vendors as Agilent Technologies, Inc., Waters Corporation,
Alltech Associates, Lachat, Inc. and other smaller companies.


The
Companys ASE 200 and 300 compete directly with standard soxhlet, sonication,
supercritical fluid extraction and microwave extraction techniques provided by other
companies. Management believes that the ASE 200 and 300, has certain benefits compared to
competing techniques, including faster extraction time, reduced solvent usage and
built-in automation.



11
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|The
Company believes that competition in the analytical instruments will continue to increase
in the future. Many of the companies whose products compete with those of the Company
have substantially greater financial resources and larger technical staffs and sales
forces at their disposal. There can be no assurances that the Companys marketing and
sales efforts will compete successfully against such other companies in the future.


Patents
and Licenses


The
Company has an extensive patent portfolio covering certain of the Companys products. The
primary benefits of patents are presently limited to the United States and certain other
foreign countries where patents have been issued.


As a
matter of Company policy, the Company vigorously protects its intellectual property
rights and seeks patent coverage on all developments that it regards as material and
patentable. However, there can be no assurances that any patents held by the Company will
not be challenged, invalidated or circumvented or that the rights granted thereunder will
provide competitive advantages to the Company. The Companys patents, including those
licensed from others, expire on various dates through 2018. The Company believes that,
while its patent portfolio has value, no single patent or patent application is in itself
essential and that the invalidity or expiration of any single patent would not have a
material adverse effect on its business.


The
Company regards its PeakNet and CHROMELEON software as proprietary and relies on a
combination of copyrights, trademarks, trade secret laws and other proprietary rights,
laws, license agreements and other restrictions on disclosure, copying and transferring
title to protect its rights to its software products. The Company has no patents covering
its software, and existing copyright laws afford only limited practical protection. In
addition, the laws of some foreign countries do not protect the Companys proprietary
rights to the same extent as do the laws of the United States.


International
Operations


Financial
information about foreign and domestic operations and export sales required by Item 1 of
  Form   10-K  is incorporated by reference to Note 12 of the Notes to Consolidated Financial
Statements at page 35 of the Registrants 2001 Annual Report to Stockholders. A copy of
the applicable page is included as Exhibit 13.1.



12
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|The
Company has subsidiaries in the United Kingdom, Germany, Italy, France, the Netherlands,
Belgium, Switzerland, Austria, Denmark, Japan, China and Canada. The Companys foreign
sales are affected by fluctuations in currency exchange rates and by regulations adopted
by foreign governments. Export sales are subject to certain controls and restrictions,
but the Company has not experienced any material difficulties related to these
limitations. There can be no assurances that the Companys results of operation will not
be adversely impacted by fluctuations in currency exchange rates in the future.


The
Companys business is dependent upon customer demand in the countries that it sells its
products. Any fluctuations in demand for analytical instrumentation can have an effect on
the Companys results of operations.


Manufacturing
and Suppliers


The
Company produces chemicals and resins and assembles systems and components in its
California manufacturing facilities. The Company assembles the systems and components for
its Summit HPLC system in its German manufacturing facility. The Company assembles the
systems and components for its UltiMate system in its Dutch manufacturing facility.
Dionex has developed proprietary processes for the manufacture of polystyrene-based
resins and for packing columns with these resins. The Company believes that its resins,
columns and suppressor manufacturing know-how are critical to the performance and
reliability of its chromatography systems. The Company requires each employee to sign a
nondisclosure agreement to protect its proprietary processes. However, there can be no
assurances that these agreements will provide meaningful protection or adequate remedies
for the Companys proprietary processes in the event of unauthorized use or disclosure.


The
Company has emphasized a modular design for the principal subsystems of its pumping flow
systems, sample injection systems, chromatography modules, detectors, and control and
data analysis systems. The Company believes that this modular approach has enabled it to
meet the wide range of system configurations required by its customers while effectively
managing inventory levels.


Many
components used in the Companys products, including proprietary analog and digital
circuitry, are manufactured by Dionex. Other components, including packaging materials,
integrated circuits, microprocessors, microcomputers and certain detector and data
analysis modules, are acquired from other manufacturers. Most of the raw materials,
components and supplies purchased by the Company are available from a number of different
suppliers; however, a number of items are purchased from limited or single sources of
supply, and disruption of these sources could have a temporary adverse effect on
shipments and the financial results of the Company. The Company believes alternative
sources could ordinarily be obtained to supply these materials, but a prolonged inability
to obtain certain materials or components could have an adverse effect on the Companys
financial condition or results of operations and could result in damage to its
relationship with its customers.



13
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Technical
Support, Installation and Service


Users
of the Companys chromatography systems require substantial technical support before and
after the system sale to ensure that analysis problems are resolved. As part of its
support services, the Companys technical support staff provides, typically at no
additional cost, individual assistance in solving chemical analysis problems. The Company
offers training courses and periodically sends its customers information on applications
development. Chromatography systems sold by the Company generally include a one-year
warranty, installation and certain user training, all at no additional cost. Service
contracts may be purchased by customers to cover equipment no longer under warranty.
Service work not performed under warranty or service contracts is performed on a time and
materials basis. The Company installs and services its products through its own field
service organization in the United Kingdom, Germany, Italy, France, the Netherlands,
Belgium, Switzerland, Austria, Denmark, Japan, China, Canada and the United States.
Installation and service in other foreign countries are typically provided by the
Companys distributors or agents.


Research
and Development


The
Companys research and development efforts are focused on increasing the performance of
its chromatography and other products and expanding the number of chemical compounds that
can be analyzed efficiently with its products. Research and product development
expenditures were $14.7 million, $14.9 million and $14.8 million in fiscal 2001, 2000 and
1999, respectively. The Company pursues active development programs in the areas of
system hardware, applications, computer software, suppressors, resin and column
technologies. There can be no assurances that the Companys product development efforts
will be successful or that the products developed will be accepted by the marketplace.


Environmental
Laws and Regulations


Compliance
by the Company with federal, state and local environmental laws during fiscal 2001 had no
material effect upon capital expenditures, earnings or its competitive position.


Employees


Dionex
had 912 employees at June 30, 2001, compared with 805 employees at June 30, 2000. The
Company believes that its future success depends in large part upon its continued ability
to attract and retain highly skilled employees.



14
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|
|

|Item 2. |  | PROPERTIES
|------- |  | ----------

|As of
September 15, 2001 the Company owned nine buildings in Sunnyvale, California, providing
252,000 square feet of space utilized for Administration, Marketing, Sales, Service,
Research and Product Development and Manufacturing. The Company also owns a building
utilized for Sales, Service and Administration in Idstein, Germany and a building for
Manufacturing and Administration in Germering, Germany. The Company also owns a building
in Osaka, Japan for sales, service and administration.


The
Company leases sales and service offices in: Atlanta, Georgia; Houston, Texas; Westmont,
Illinois; Marlton, New Jersey; Sunnyvale, California; and in the United Kingdom, Germany,
France, Italy, the Netherlands, Belgium, Switzerland, Austria, Denmark, Japan, China and
Canada. In addition, the Company leases marketing and research and development offices in
Salt Lake City, Utah. The Companys facilities are well maintained, adequate to conduct
the Companys current business and substantially utilized by the Company.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 3. |  | LEGAL PROCEEDINGSNone.
|------- |  | ----------------------

|Item 4. |  | SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDER
 No matters were submitted to a vote of security holders
 during the quarter ended June 30, 2001.
|------- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------

|15
|--

|Executive
Officers of the Registrant



The
following table lists the names and positions of all current executive officers of the
Company, and their ages as of September 15, 2001. Except as noted below, there are no
other family relationships between any director or executive officer and any other
director or executive officer of the Registrant. Executive officers serve at the
discretion of the Board of Directors.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | Name | Age                    | Positions |   
| | ---- | ---------------------- | --------- | --
|
| |      | A. Blaine Bowman (1)   |           | 55
|
| |      | Barton Evans, Jr.      |           | 53
|
| |      | Nebojsa Avdalovic      |           | 66
|
| |      | Der-Min Fan ́           |           | 51
|
| |      | Peter Jochum           |           | 50
|
| |      | Craig A. McCollam      |           | 41
|
| |      | Brent J. Middleton (1) |           | 44
|
| |      | Christopher Pohl       |           | 50
|
| |      | Jeffrey Thompson       |           | 45

| | (1) Mr. Bowman and Mr. Middleton are cousins.
| | ---------------------------------------------

|Mr.
Bowman has served as the Registrants President and Chief Executive Officer and as a
director since the Registrant began operations in 1980. Mr. Bowman is also a director of
Molecular Devices Corporation.


Mr.
Evans has served as Executive Vice President and Chief Operating Officer for the
Registrant since January 2001. Prior to that, he served as Senior Vice President,
Operations and in various other capacities for the Registrant since it began operations
in 1980.


Dr.
Avdalovic has served as Vice President and Chief Technology Officer for the Registrant
since June 2001. Prior to that he served as Vice President, Research and Development for
the Registrant since August 1990.


Ms.
Fan has served as Vice President, Software Engineering for the Registrant since April
2000. Prior to that, she served as Director of Software Engineering and in various other
capacities since joining the Company in 1991.



16
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Mr.
Jochum has served as Vice President, Germering Operations since October 2000. He served
as Manager Director of Dionex Softron since October 1998. Prior to that he served as
Managing Director of Softron GmbH.


Mr.
McCollam has served as Vice President of Finance and Administration and Chief Financial
Officer since October 1999. Prior to that, he served as Director of Finance and Corporate
Controller since joining the Company in 1993.


Mr.
Middleton has served as Vice President, North American Sales and Service since July 1997.
Prior to that, he served as Director of North American Sales and Service and in various
other capacities since joining the Company in 1985.


Mr.
Pohl has rejoined the Registrant as Vice President, Research and Development in June
2001. From March 2000 to June 2001, Mr. Pohl served as Vice President, Research and
Development of Ciphergen Biosystems, Inc. Prior to that, he served as Technical Director
and in various other capacities for the Registrant since the Company began operations in
1980.


Mr.
Thompson has served as Vice President, Instrument Engineering since May 2001. Prior to
that, he served as Director of Instrument Engineering and in various other capacities
since joining the company in 1980.


17
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|PART II
|-------

|Item 5. |  | MARKET FOR REGISTRANTS COMMON STOCK AND RELATEDSTOCKHOLDER MATTERS
|------- |  | -------------------------------------------------------------------

| |  | The information
required by Item 5 of Form 10-K is incorporated by reference to the information contained
in the section captioned Supplemental Stockholder Information at page 38 of the
Registrants 2001 Annual Report to Stockholders. A copy of the applicable page is
attached hereto as Exhibit 13.1.
| |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 6. |  | SELECTED CONSOLIDATED FINANCIAL DATA
|------- |  | ------------------------------------

| |  | The information
required by Item 6 of Form 10-K is incorporated by reference to the information contained
in the section captioned Selected Financial Information at page 20 of the Registrants
2001 Annual Report to Stockholders. A copy of the applicable page is attached hereto as
Exhibit 13.1.
| |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 7. |  | MANAGEMENTS DISCUSSION AND ANALYSISOF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|------- |  | ------------------------------------------------------------------------------------

| |  | The information
required by Item 7 of Form 10-K is incorporated by reference to the information contained
in the section captioned Managements Discussion and Analysis of Results of Operations
and Financial Condition on pages 15-19 of Registrants 2001 Annual Report to
Stockholders.
| |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 7A. |  | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|-------- |  | ----------------------------------------------------------

| |  | The information
required by Item 7A of Form 10-K is incorporated by reference to the information
contained in the section captioned Managements Discussion and Analysis of Results of
Operations and Financial Condition on pages 18 and 19 of Registrants 2001 Annual Report
to Stockholders.
| |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 8. |  | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|------- |  | -------------------------------------------

| |  | See Index
to Financial Statements and Financial Statement Schedules appearing on page of this Form
10-K.
| |  | --------------------------------------------------------------------------------------------------------

|Item 9. |  | CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|------- |  | ------------------------------------------------------------------------------------

| |  | Not Applicable.
| |  | ---------------

|18
|--

|PART III
|--------

|Item 10. |  | DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
|-------- |  | --------------------------------------------------

| |  | Identification of Directors
| |  | ---------------------------

| |  | The information
required by Item 10 of Form 10-K with respect to identification of directors is
incorporated by reference to the information contained in the section captioned
Nominees at pages 3 and 4 of the Registrants definitive Proxy Statement for the Annual
Meeting of Stockholders to be held October 26, 2001, which has been previously filed.
| |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Identification of Officers
| |  | --------------------------

| |  | See Pages 16 and 17 of this Report.
| |  | -----------------------------------

|Item 11. |  | EXECUTIVE COMPENSATION
|-------- |  | ----------------------

| |  | The information
required by Item 11 of Form 10-K is incorporated by reference to the information
contained in the section captioned Executive Compensation, at pages 8 through 9 of the
Registrants definitive Proxy Statement for the Annual Meeting of Stockholders to be held
October 26, 2001, which has been previously filed.
| |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 12. |  | SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|-------- |  | --------------------------------------------------------------

| |  | The information
required by Item 12 of Form 10-K is incorporated by reference to the information
contained in the sections captioned Security Ownership of Certain Beneficial Owners and
Management at pages 6 and 7 of the Registrants definitive Proxy Statement for the
Annual Meeting of Stockholders to be held October 26, 2001, which has been previously
filed.
| |  | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Item 13. |  | CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
|-------- |  | ----------------------------------------------

| |  | None.
| |  | -----

|19
|--

|PART IV
|-------

|Item 14. |  | EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ONFORM 8-K
|-------- |  | --------------------------------------------------------------

| |  |  |  |  |  |  |  | 
| |  |  |  |  |  |  |  | 

| |  |  |  | (a) |  | (1) |  | Financial
Statements - See Index to Financial Statements and Financial Statement Schedules at page
25 of this Report.
| |  |  |  | --- |  | --- |  | ---------------------------------------------------------------------------------------------------------------------

| |  |  |  |  |  | (2) |  | Financial
Statement Schedules - See Index to Financial Statements and Financial Statement Schedules
at page 25 of this Report.
| |  |  |  |  |  | --- |  | ------------------------------------------------------------------------------------------------------------------------------

| |  |  |  |  |  | (3) |  | Exhibits
- See Exhibit Index at page 21 through of this Report.
| |  |  |  |  |  | --- |  | ---------------------------------------------------------------

| |  |  |  | (b) |  | Reports
on Form 8-K - The Company did not file any reports on Form 8-K during the quarter ended
June 30, 2001.
| |  |  |  | --- |  | --------------------------------------------------------------------------------------------------------------

|20
|--

|DIONEX CORPORATION


EXHIBIT INDEX
|----------------------------------

|ExhibitNumber | Description | Reference                                                                                                                                                           
|------------- | ----------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1           |             | Restated Certificate of Incorporation,    filed November 6, 1996                                                                                                    
|             
|3.2           |             | Bylaws, as amended on March 10, 1998                                                                                                                                
|             
|4.1           |             | Shareholder Rights Agreement dated June 27, 1999,    between the Registrant and The First National    Bank of Boston                                                
|             
|10.1          |             | Agreement, effective as of January 1, 1975,    between The Dow Chemical Company and    International Plasma Corporation                                             
|             
|10.2          |             | Memorandum agreement, dated March 14, 1975,    between The Dow Chemical Company and    International Plasma Corporation                                             
|             
|10.3          |             | Agreement, dated March 6, 1975, between    International Plasma Corporation and the    former Dionex Corporation                                                    
|             
|10.4          |             | Consent to Assignment executed as of March 26,    1980, between the Dow Chemical Company and the    former Dionex Corporation                                       
|             
|10.5          |             | Amendatory Agreement, effective as of November 1,    1981, between The Dow Chemical Company and the    Registrant (with certain confidential information    deleted)
|             
|10.6          |             | Amendatory Agreement, effective as of July 1, 1982,    between The Dow Chemical Company and the    Registrant (with certain confidential information    deleted)    
|             
|10.7          |             | Registrants Supplemental Stock Option Plan    (Exhibit 28.4)                                                                                                       
|             
|10.8          |             | Registrants Medical Care Reimbursement Plan    (Exhibit 10.17)                                                                                                     
|             
|10.9          |             | Registrants Employee Stock Participation Plan    (Exhibit 28.3)                                                                                                    

|21
|--

|
|

|ExhibitNumber | Description | Reference                                                                                                                                     
|------------- | ----------- | ----------------------------------------------------------------------------------------------------------------------------------------------
|10.10         |             | Credit Agreement dated February 26, 1996    between Bank of America and the Registrant..                                                      
|             
|10.11         |             | First amendment to Credit Agreement dated    February 29, 1996 between Bank of America and the    Registrant                                  
|             
|10.12         |             | Second amendment to Credit Agreement dated    February 29, 1996 between Bank of America    and the Registrant                                 
|             
|10.13         |             | Third amendment to Credit Agreement dated    February 29, 1996 between BankAmerica and the    Registrant.(Exhibit 10.1)                       
|             
|10.14         |             | Credit Agreement dated November 13, 2000    between Wells Fargo Bank and the    Registrant (Exhibit 10.15)                                    
|             
|10.15         |             | 1988 Directors Stock Option Plan (and related    stock option grant form) (Exhibit 10.20)                                                    
|             
|10.16         |             | Dionex Corporation Stock Option Plan, as    amended and restated (formerly, the 1990 Stock    Option Plan).(Exhibit 10.12)                    
|             
|13.1          |             | Portions of the Registrants 2001 Annual    Report to Stockholders that are incorporated    by reference in this Annual Report on    Form 10-K
|             
|21.1          |             | Subsidiaries of Registrant                                                                                                                    
|             
|23.1          |             | Independent Auditors Consent                                                                                                                 

|(1) |  | Incorporated
by reference to the indicated exhibit in Amendment No. 1 of the Registrants Registration
Statement on Form S-1 filed December 7, 1982.
|--- |  | ----------------------------------------------------------------------------------------------------------------------------------------------------

|(2) |  | Incorporated by reference to the indicated exhibit in the Registrants
Registration Statement on Form S-8 filed March 3, 1987.
|--- |  | ------------------------------------------------------------------------------------------------------------------------------

|(3) |  | Incorporated by reference to the indicated exhibit in the Registrants
Annual Report on Form 10-K filed September 27, 1988.
|--- |  | ---------------------------------------------------------------------------------------------------------------------------

|(4) |  | Incorporated by reference to the indicated exhibit in the Registrants
Statement on Form S-8 filed May 6, 1994.
|--- |  | ---------------------------------------------------------------------------------------------------------------

|(5) |  | Incorporated
by reference to the corresponding exhibit in the Registrants Annual Report on Form 10-K
filed September 26, 1996.
|--- |  | -------------------------------------------------------------------------------------------------------------------------------

|22
|--

|
|

|(6) |  | Incorporated by reference to the corresponding exhibit in the Registrants
Quarterly Report on Form 10-Q filed February 13, 1997.
|--- |  | ---------------------------------------------------------------------------------------------------------------------------------

|(7) |  | Incorporated by reference to the corresponding exhibit in the Registrants
Annual Report on Form 10-K filed September 28, 1998.
|--- |  | -------------------------------------------------------------------------------------------------------------------------------

|(8) |  | Incorporated by reference to the indicated exhibit in the Registrants
Quarterly Report on Form 10-Q filed November 16, 1998.
|--- |  | -----------------------------------------------------------------------------------------------------------------------------

|(9) |  | Incorporated by reference to the corresponding exhibit in the Registrants
Quarterly Report on Form 10-Q filed February 16, 1999.
|--- |  | ---------------------------------------------------------------------------------------------------------------------------------

|(10) |  | Incorporated by reference to the indicated exhibit in the Registrants
Statement on Form S-8 filed December 22, 1999.
|---- |  | ---------------------------------------------------------------------------------------------------------------------

|(11) |  | Incorporated
by reference to the indicated exhibit in the Registrants Quarterly Report on Form 10-Q
filed November 14, 2001.
|---- |  | -----------------------------------------------------------------------------------------------------------------------------

|23
|--

|SIGNATURES



Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Date September 24, 2001 |  | DIONEX CORPORATION(Registrant)By: /s/ A. Blaine Bowman
A. Blaine BowmanPresident and Chief ExecutiveOfficer
|----------------------- |  | -------------------------------------------------------------------------------------------------------------------------

|Pursuant to the
requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the Registrant and in the capacities
and on the dates indicated.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Signature                                                 | Title | Date                                                                                                    
|--------------------------------------------------------- | ----- | --------------------------------------------------------------------------------------------------------
|/s/ A. Blaine BowmanA. Blaine Bowman              |       | President, Chief Executive
             Officer, and Director
             (Principal Executive Officer)
|                                                         
|/s/ Craig A. McCollam
       Craig A. McCollam    |       | Vice President of Finance and Administration
       (Principal Financial and
       Accounting Officer) 
|                                                         
|/s/ David L. Anderson
       David L. Anderson    |       | Director                                                                                                
|                                                         
|/s/ James F. Battey
       James F. Battey        |       | Director                                                                                                
|                                                         
|/s/ B.J. Moore 
       B.J. Moore                 |       | Director                                                                                                
|                                                         
|/s/ Riccardo Pigliucci 
       Riccardo Pigliucci |       | Director                                                                                                
|                                                         

|24
|--

|DIONEX CORPORATION


INDEX TO FINANCIAL
STATEMENTS AND FINANCIAL STATEMENT SCHEDULES
|------------------------------------------------------------------------------------

|                                                      | Page
|----------------------------------------------------- | ----
|FINANCIAL STATEMENTS                                  |     
|                                                     
|Consolidated Balance Sheets at June 30, 2001 and 2000 |     
|                                                     
|Consolidated Statements of Income for the years       |     
|ended June 30, 2001, 2000 and 1999                    |     
|                                                     
|Consolidated Statements of Stockholders Equity for   |     
|the years ended June 30, 2001, 2000 and 1999          |     
|                                                     
|Consolidated Statements of Cash Flows for the years   |     
|ended June 30, 2001, 2000 and 1999                    |     
|                                                     
|Notes to Consolidated Financial Statements            |     
|                                                     
|Independent Auditors Report                          |     

|* |  | Incorporated
by reference to information contained on pages 24 through 38 of the
Registrants 2001 Annual Report to Stockholders. A copy of the applicable
pages is attached hereto as Exhibit 13.1
|- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|FINANCIAL STATEMENT SCHEDULES
|-----------------------------

|Independent Auditors Report                    |  | 29 | 
|----------------------------------------------- |  | -- | 
|                                               
|Schedule II - Valuation and Qualifying Accounts | 
|and Reserves                                    |  | 30 | 

|All other schedules are
omitted because they are not required, are not applicable or the information is
included in the consolidated financial statements or notes thereto.

25
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|INDEPENDENT AUDITORS REPORT


Dionex Corporation


We have audited the consolidated
financial statements of Dionex Corporation and its subsidiaries as of June 30, 2001 and
2000, and for each of the three years in the period ended June 30, 2001, and have issued
our report thereon dated July 30, 2001; such financial statements and report are included
in your 2001 Annual Report to Stockholders and are incorporated herein by reference. Our
audits also included the consolidated financial statement schedule of Dionex Corporation
and its subsidiaries, listed in the accompanying Index to Financial Statements and
Financial Statement Schedules. This financial statement schedule is the responsibility of
the Companys management. Our responsibility is to express an opinion based on our
audits. In our opinion, such financial statement schedule, when considered in relation to
the basic consolidated financial statements taken as a whole, presents fairly in all
material respects the information set forth therein.

DELOITTE & TOUCHE LLP


San Jose, CaliforniaJuly 30, 2001

26
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|SCHEDULE II



DIONEX CORPORATIONVALUATION AND
QUALIFYING ACCOUNTS AND RESERVESYEARS ENDED JUNE 30,
2001, 2000 AND 1999(IN THOUSANDS)
|-------------------------------------------------------------------------------------------------------------------------------------

|                          | BalanceBeginningof Year | Additions | Charged(Credited)to OtherAccounts (1) | Deductions | BalanceEnd ofYear
|------------------------- | ----------------------- | --------- | ------------------------------------- | ---------- | -----------------
|                         
|YEAR ENDED JUNE 30, 2001: |                         |           |                                       |            |                  
|                         
|Allowance for             |                         |          
|doubtful accounts         |                         |           | $                                     | 765        |                  
|                         
|Accrued product warranty  |                         |          
|and installation          |                         |           | $                                     | 4,645      |                  
|                         
|                         
|YEAR ENDED JUNE 30, 2000: |                         |          
|                         
|Allowance for             |                         |          
|doubtful accounts         |                         |           | $                                     | 812        |                  
|                         
|Accrued product warranty  |                         |          
|and installation          |                         |           | $                                     | 4,701      |                  
|                         
|                         
|YEAR ENDED JUNE 30, 1999: |                         |          
|                         
|Allowance for             |                         |          
|doubtful accounts         |                         |           | $                                     | 606        |                  
|                         
|Accrued product warranty  |                         |          
|and installation          |                         |           | $                                     | 4,013      |                  
|                         

|(1) |  | Effects
of exchange rate changes
|--- |  | --------------------------------

|(2) |  | Accounts
written off, net of recoveries
|--- |  | ---------------------------------------

|(3) |  | Product
warranty and installation costs
|--- |  | ---------------------------------------

|27
|--